secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2026-04-09T23:59:59+00:00
Accession:  0001683168-26-002781
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma reports FY 2025 revenue $36.3M (+4.1% YoY), net loss $5.98M
------------------------------------------------------------------------------

- Revenue $36.31M vs $34.87M in 2024; gross profit $12.26M up from $10.67M.
- Net loss widened to $5.98M from $5.13M, including $1.75M non-cash impairment charge.
- Launched 9 new generic drugs in 2025, portfolio now 71 products; 12 more planned in 2026.
- Raised $2.46M gross via registered direct offering to expand sales operations.
- Cost-reduction initiatives expected to cut G&A by $2M-$3M in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316826002781/0001683168-26-002781-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316826002781/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-002781

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer